Omega Diagnostics receives positive study data on lateral flow antigen test

Medical diagnostics company Omega said on Tuesday that study data on its Mologic Covid-19 lateral flow antigen test showed "high diagnostic accuracy", exceeding World Health Organisation targets.

Omega said the study concluded that the Mologic test, which has been commercialised by Omega as the VISITECT Covid-19 Antigen test, had fulfilled the WHO target diagnostic accuracy with a high sensitivity of 93.2%-98.4%, detecting individuals with high viral load infections.

The AIM-listed group added that the study also concluded that the Mologic test replicated diagnostic accuracy in a variety of settings important for Covid-19 control and on self-collected swab specimens.

Chief executive Colin King said: "This is great news for the Mologic test, which we are now producing under our VISITECT brand. It is significant that the test has been shown to have high diagnostic accuracy, but also that this performance is replicated across multiple different settings, different demographics, and on self-collected swab specimens."

As of 0845 BST, Omega shares were down 0.73% at 65.52p.